Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.
Baystreet.ca News Commentary — The global precision oncology market is on pace to reach $303 billion in 2035[1], a figure that reflects more than steady growth, signaling a structural ...
Money Talks News on MSN
New pancreatic cancer treatment tracks tumors through your entire body
Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in lab studies, though long-term safety in humans remains unknown.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results